Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Metabolic Effects of Duodenal Jejunal Bypass Liner for Type 2 Diabetes Mellitus (DJBL-T2DM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02800668
Recruitment Status : Completed
First Posted : June 15, 2016
Last Update Posted : June 15, 2016
Sponsor:
Information provided by (Responsible Party):
Diethelm Tschoepe, Ruhr University of Bochum

Brief Summary:

Implantation of a duodenal-jejunal endoluminal bypass liner (DJBL) has shown to induce weight loss and to improve metabolic parameters. DJBL is a reversible endoduodenal sleeve mimicking biliodigestive digestion while lacking risks and limitations of bariatric surgery.

Effects on metabolic control, body mass parameters, appetite regulation, glucose tolerance, organ health, and lipid profile were determined in 16 morbidly overweight patients with type 2 diabetes mellitus. In addition, relevant hormones (Leptin, ghrelin, gastric inhibitory peptide, glucagon-like peptide 1, and insulin) were measured by enzyme-linked immunosorbent assay (ELISA) and chemiluminescent microparticle immunoassay (CMIA) at 0, 1 and 32, and 52 weeks post-implant following a mixed meal tolerance test, which was applied for diagnostic purposes only.


Condition or disease Intervention/treatment
Type 2 Diabetes Mellitus Obesity Device: DJBL (Duodenal jejunal bypass liner, EndoBarrier)

Detailed Description:

A total of 18 subjects (4 women and 14 men) aged 39 to 66 years underwent implantation of the DJBL.The subjects were regular patients of the Diabetes Center at the Herz- und Diabeteszentrum Nordrhein-Westfalen (HDZ NRW), Germany and gave informed consent for related procedures and data handling. The subjects had body mass index (BMI) ≥35 kg/m2, type 2 diabetes mellitus (T2DM), and a history of frustrated weight loss attempts. Exclusion criteria were: history of gastric surgery, gastric or duodenal ulcers, thyroid disorders, gastrointestinal disorders associated with intestinal resorption dysfunction, therapy with oral anticoagulants like marcumar, use of acetyl salicylic acid or non-steroidal anti-inflammatory drugs, drug abuse (incl. alcohol), symptomatic cardiovascular disease including heart failure New York Heart Association (NYHA) IV, renal insufficiency defined as glomerular filtration rate (GFR) <50 ml/min, pregnancy or breast feeding.

Study design All patients received the DJBL due to medical reasons, not for study purposes. All patients underwent pre-implantation and follow-up examinations (1 week, 32 weeks and 52 (explantation) weeks after implantation). Every examination included a thorough body examination, electrocardiogram (ECG), and the body composition measurement by bio-impedance scaling (type: BC418MA, Tanita, Amsterdam, the Netherlands). Upon implantation, antidiabetic medication was adapted, patients were followed up to adjust antidiabetic regimen. Dietary advice was given to the patients by a professional dietician upon implantation procedure, and liquid diet was started the day before implantation and continued for two additional days followed by puréed diet for four days. Patients decided to turn back to normal diet upon tolerance; fibre rich dietary components were prohibited during the treatment period. Treatment with glucagon-like peptide-1 (GLP-1) or dipeptidyl-peptidase-4 (DPP4) based medication (Exenatide, Liraglutide, Lixisenatide or Sitagliptin, Vildagliptin) was initiated in cases that fasting C-peptide levels were >750 pmol/l. Insulin dosage was reduced after implantation to avoid risk of hypoglycaemia. Sulfonylurea treatment was stopped after implantation.

Mixed meal tolerance tests Mixed meal tolerance tests (MMTT) were performed in fasting state as routine diagnostic tool to assess metabolism parameters and gut hormones described below. In the course of a MMTT every patient consumed a highly caloric drink (Fortimel regular 2 093 Kilojoules (KJ), Nutricia GmbH, Erlangen, Germany) containing carbohydrates (41 energy(EN)%), proteins (40 EN%) and fats (19 EN%), simulating an average meal. Blood samples were taken at fixed intervals: before drinking, after 10, 30, 60, 90, 120 min. DPP4 inhibitor was added to prevent autodigestion of GLP-1 immediately after sampling, Hydroxymercuribenzoic acid was added to plasma per protocol to prevent ghrelin digestion. Samples were stored after centrifugation at -80°C until assayed for the gut hormones ghrelin, GLP-1, gastric inhibitory peptide, leptin as well as the metabolism parameters glucose, insulin, C-peptide, and proinsulin.

Biochemical assessment Laboratory assessments were done in fasting state. Venipuncture was performed the morning after overnight fasting one day before the planned procedure, one week, 8, and 12 months after implantation. Blood samples were processed for subsequent analysis within 20 min of venipuncture. Serum concentrations were measured by commercial available kits of total ghrelin (ELISA, Merck Chemicals Gesellschaft mit beschränkter Haftung (GmbH), Schwalbach, Germany), leptin (ELISA, DRG-International, Inc., USA), active GLP-1 (ELISA, epitope Diagnostics, San Diego, USA), gastric inhibitory Peptide (GIP) (ELISA, DRG-International, Inc., USA), Insulin (CMIA, Abbott, Wiesbaden, Germany), C-peptide (CMIA, Abbott, Wiesbaden, Germany), Proinsulin (ELISA, TecoMedical Bunde, Germany) and glucose (CMIA, Abbott, Wiesbaden Germany).

Layout table for study information
Study Type : Observational
Actual Enrollment : 19 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Metabolic Effects of Duodenal Jejunal Bypass Liner for the Treatment of Adipose Patients With Type 2 Diabetes Mellitus
Study Start Date : October 2011
Actual Primary Completion Date : June 2015
Actual Study Completion Date : June 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Weight Control

Group/Cohort Intervention/treatment
DJBL implant-group

T2DM Patients implanted with a DJBL (Duodenal jejunal Bypass liner, EndoBarrier, GI Dynamics) due to medical reasons.

The subjects were regular in-patients of the Diabetes Center at the Heart and Diabetes Center NRW, Germany and gave informed consent for related procedures and data handling. The subjects had BMI ≥35 kg/m2, T2DM, and a history of frustrated weight loss attempts. Exclusion criteria: history of gastric surgery, gastric or duodenal ulcers, thyroid disorders, gastrointestinal disorders with intestinal resorption dysfunction, therapy with oral anticoagulants, use of acetyl salicylic acid or non-steroidal anti-inflammatory drugs, drug abuse (incl. alcohol), symptomatic cardiovascular disease, renal insufficiency (GFR <50 ml/min), pregnancy or breast feeding.

Device: DJBL (Duodenal jejunal bypass liner, EndoBarrier)
Implantation of EndoBarrier after medical and patient's decision, Duration of treatment 12 months in maximum, follow up for 4 weeks after Explantation, follow up during treatment by physical examination, ECG control, sampling and analysis of blood parameters, mixed meal tolerance tests only for diagnostic purposes to assess gut hormonal changes and metabolic parameters
Other Name: EndoBarrier




Primary Outcome Measures :
  1. weight loss in kg [ Time Frame: 12 months ]
    weight loss defined as excess weight loss


Secondary Outcome Measures :
  1. Change in body fat in %, measured via bioimpedance scaling [ Time Frame: 12 months ]
    effect of DJBL on body composition in overweight T2DM patients determined by bioimpedance scaling

  2. Change in HbA1c in mmol/mol [ Time Frame: 12 months ]
    effect of DJBL on metabolic regulation in overweight T2DM patients

  3. Change in LDL-cholesterol in mg/dl [ Time Frame: 12 months ]
    effect of DJBL on metabolic regulation in overweight T2DM patients

  4. Change in triglycerides in mg/dl [ Time Frame: 12 months ]
    effect of DJBL on metabolic regulation in overweight T2DM patients

  5. Change in liver enzyme aspartate aminotransferase (ASAT) in U/l [ Time Frame: 12 months ]
    effect of DJBL on metabolic regulation in overweight T2DM patients

  6. Change in liver enzyme alanine aminotransferase (ALAT) in U/l [ Time Frame: 12 months ]
    effect of DJBL on metabolic regulation in overweight T2DM patients

  7. changes in intestinal enzyme levels (GLP-1) in pmol/l/120 min during mixed meal tolerance test [ Time Frame: 12 months ]
    effect of DJBL and intestine/pancreatic axis for metabolic control

  8. changes in intestinal enzyme levels (GIP) in ng/ml/120 min during mixed meal tolerance test [ Time Frame: 12 months ]
    effect of DJBL and intestine/pancreatic axis for metabolic control

  9. changes in Ghrelin in ng/ml/120 min during mixed meal tolerance test [ Time Frame: 12 months ]
    effect of DJBL and intestine/pancreatic axis for metabolic control

  10. changes in Leptin in ng/ml/120 min during mixed meal tolerance test [ Time Frame: 12 months ]
    effect of DJBL and intestine/pancreatic axis for metabolic control

  11. changes in pancreatic enzyme levels (Insulin) in U/l/120 min during mixed meal tolerance test [ Time Frame: 12 months ]
    effect of DJBL and intestine/pancreatic axis for metabolic control

  12. changes in pancreatic enzyme levels (Proinsulin) in nmol/l/120 min during mixed meal tolerance test [ Time Frame: 12 months ]
    effect of DJBL and intestine/pancreatic axis for metabolic control

  13. effect on blood pressure measured in mmHg [ Time Frame: 12 months ]
    follow up by regular vital signs,


Biospecimen Retention:   Samples Without DNA
Blood sampling during study, analysis via ELISA for special markers at study end in one batch, active medical control parameters like HbA1c, cholesterol, hemogram etc. at visits


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The subjects were regular inpatients with type 2 Diabetes mellitus of the Diabetes Center at the Heart and Diabetes Center NRW, Germany and gave informed consent for related procedures and data handling
Criteria

Inclusion Criteria:

  • T2DM
  • body mass index (BMI) ≥35 kg/m2
  • history of frustrated weight loss attempts

Exclusion Criteria:

  • history of gastric surgery, gastric or duodenal ulcers
  • thyroid disorders
  • gastrointestinal disorders associated with intestinal resorption dysfunction
  • therapy with oral anticoagulants like marcumar
  • use of acetyl salicylic acid or non-steroidal anti-inflammatory drugs
  • drug abuse (incl. alcohol)
  • symptomatic cardiovascular disease including heart failure New York Heart Association IV
  • renal insufficiency defined as GFR <50 ml/min
  • pregnancy or breast feeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02800668


Locations
Layout table for location information
Germany
Herz- und Diabeteszentrum
Bad Oeynhausen, Germany, 32545
Sponsors and Collaborators
Ruhr University of Bochum
Investigators
Layout table for investigator information
Principal Investigator: Diethelm Tschoepe, Prof MD Herz und Diabeteszentrum NRW
Layout table for additonal information
Responsible Party: Diethelm Tschoepe, Prof. Dr. Dr., Ruhr University of Bochum
ClinicalTrials.gov Identifier: NCT02800668    
Other Study ID Numbers: DJBL-HDZ
First Posted: June 15, 2016    Key Record Dates
Last Update Posted: June 15, 2016
Last Verified: June 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: after publication of results
Keywords provided by Diethelm Tschoepe, Ruhr University of Bochum:
Duodenal Jejunal Bypass Liner
obesity
weight loss therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases